Venture Capital, Private Equity Investors Keep Pumping Cash Into China CGT Space
Executive Summary
Among the latest financing deals, advanced therapeutics such as cell and gene therapies (CGT) continued enjoying the spotlight from venture capital and private equity investors in China. Meanwhile, small molecules with novel mechanism of action such as molecule glue stood out from their peers to win investors’ favor.
You may also be interested in...
Hong Kong's Immuno Cure Emerges With DNA Vaccine Approach To HIV
Hong Kong-based Immuno Cure expects its therapeutic DNA vaccine for HIV/AIDS will soon deliver early Phase I results in patients with late-stage infections, CEO Xia Jin tells Scrip in an interview, also touching on the local biotech ecosystem.
Finance Watch: VC Mega-Rounds Make A Comeback In March
Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.
China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.